/IMNM
IMNM Stock - Immunome, Inc.
Healthcare|BiotechnologyNASDAQ
$21.44+7.47%
+$1.49 (+7.47%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.33
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+68.8%upside
Target: $36.19
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMNM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.23 – $21.65
TARGET (TP)$36.20
STOP LOSS$19.72
RISK/REWARD1:8.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.18
52W High$25.30
52W Low$5.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.04M | $14.02M | N/A | N/A | N/A |
| Gross Profit | $9.04M | $14.02M | N/A | N/A | $-755,000 |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-305,800,000 | $-109,530,000 | $-36,901,000 | $-25,204,000 | $-12,261,000 |
| Net Income | $-292,963,000 | $-106,806,000 | $-36,896,000 | $-24,711,000 | $-17,837,000 |
| Net Margin | -3240.4% | -761.9% | N/A | N/A | N/A |
| EPS | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-1.69 |
Company Overview
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$27
Average Target
↑ 25.5% Upside
Now
$12
Low
$27
Average
$36
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | Truist | Initiation | Buy | $36 |
| September 22nd 2025 | Goldman | Initiation | Buy | $26 |
| September 5th 2025 | Craig Hallum | Initiation | Buy | $26 |
| April 2nd 2025 | Lake Street | Initiation | Buy | $23 |
| November 8th 2024 | Stephens | Initiation | Overweight | $30 |
| May 31st 2024 | Piper Sandler | Initiation | Overweight | $27 |
| April 30th 2024 | JP Morgan | Initiation | Overweight | $24 |
| April 15th 2024 | Guggenheim | Initiation | Buy | $35 |
| January 29th 2024 | Leerink Partners | Initiation | Outperform | $30 |
| December 19th 2023 | Wedbush | Initiation | Outperform | $12 |
Earnings History & Surprises
IMNMBeat Rate
33%
Last 18 quarters
Avg Surprise
-45.9%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-0.65
Q4 2025
EPS Surprise History
Q1 24
-92.9%
$-0.54vs$-0.28
Q2 24
+57.5%
$-0.34vs$-0.80
Q3 24
-28.9%
$-0.49vs$-0.38
Q4 24
-30.0%
$-0.78vs$-0.60
Q1 25
-23.5%
$-0.84vs$-0.68
Q2 25
+21.2%
$-0.52vs$-0.66
Q3 25
+3.8%
$-0.50vs$-0.52
Q4 25
-14.0%
$-0.65vs$-0.57
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | $-0.65 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.57 | $-0.65 | -14.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.52 | $-0.50 | +3.8% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.66 | $-0.52 | +21.2% | ✓ BEAT |
Q1 2025 | Mar 19, 2025 | $-0.68 | $-0.84 | -23.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.60 | $-0.78 | -30.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.38 | $-0.49 | -28.9% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.80 | $-0.34 | +57.5% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.28 | $-0.54 | -92.9% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.17 | $-0.36 | -111.8% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.16 | $-0.46 | -187.5% | ✗ MISS |
Q2 2023 | May 5, 2023 | $0.59 | $-0.35 | -159.3% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $0.67 | $-0.64 | -195.5% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.76 | $-0.75 | +1.3% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $-0.75 | $-0.74 | +1.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.69 | $-0.96 | -39.1% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.81 | $-0.66 | +18.5% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.50 | $-0.65 | -30.0% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.39 | $-0.46 | -17.9% | ✗ MISS |
Latest News
Immunome shares are trading lower after the company announced the pricing of a public offering of 18.625 million shares at $21.50 per share.
📉 NegativeBenzinga•Dec 17, 2025, 01:59 PM
Reported Earlier, Immunome Prices Public Offering Of 18,625,000 Common Shares At $21.50 Per Share
➖ NeutralBenzinga•Dec 17, 2025, 06:55 AM
Lake Street Maintains Buy on Immunome, Raises Price Target to $32
📈 PositiveBenzinga•Dec 16, 2025, 07:22 PM
Evercore ISI Group Maintains Outperform on Immunome, Raises Price Target to $40
📈 PositiveBenzinga•Dec 16, 2025, 02:27 PM
Guggenheim Maintains Buy on Immunome, Raises Price Target to $35
📈 PositiveBenzinga•Dec 16, 2025, 01:48 PM
Immunome Announces $400M Offering
📈 PositiveBenzinga•Dec 15, 2025, 09:02 PM
Immunome shares are trading higher after the company announced topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat met its primary endpoint.
📈 PositiveBenzinga•Dec 15, 2025, 03:47 PM
Immunome Announced Registrational Trial Met Primary Endpoint, With Varegacestat Significantly Improving Progression-Free Survival Vs. Placebo
📈 PositiveBenzinga•Dec 15, 2025, 12:03 PM
Reported Sunday, Immunome Schedules Webcast To Disclose Phase 3 RINGSIDE Topline Results For Varegacestat In Desmoid Tumors
➖ NeutralBenzinga•Dec 15, 2025, 07:23 AM
Truist Securities Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $36
📈 PositiveBenzinga•Dec 1, 2025, 02:21 PM
Stephens & Co. Maintains Overweight on Immunome, Raises Price Target to $33
📈 PositiveBenzinga•Nov 17, 2025, 12:59 PM
Immunome Q3 EPS $(0.65) Misses $(0.58) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 10:10 PM
Immunome Presented Preclinical Data Showing Its Proprietary Antibody-Drug Conjugate Payload HC74 Overcomes Multiple Mechanisms Of ADC Resistance, Including Payload Efflux And Target Heterogeneity, At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
📈 PositiveBenzinga•Oct 23, 2025, 04:02 PM
Goldman Sachs Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $26
📈 PositiveBenzinga•Sep 22, 2025, 11:57 AM
Infinimmune Enters Research Collaboration With Immunome, Under Which. Immunome Will Receive Target Exclusivity
📈 PositiveBenzinga•Sep 18, 2025, 12:07 PM
Craig-Hallum Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $26
📈 PositiveBenzinga•Sep 5, 2025, 02:05 PM
Guggenheim Reiterates Buy on Immunome, Maintains $25 Price Target
📈 PositiveBenzinga•Aug 25, 2025, 02:27 PM
Evercore ISI Group Initiates Coverage On Immunome with Outperform Rating, Announces Price Target of $18
📈 PositiveBenzinga•Aug 22, 2025, 04:50 PM
Frequently Asked Questions about IMNM
What is IMNM's current stock price?
Immunome, Inc. (IMNM) is currently trading at $21.44 per share. The stock has moved +7.47% today.
What is the analyst price target for IMNM?
The average analyst price target for IMNM is $36.20, based on 1 analyst.
What sector is Immunome, Inc. in?
Immunome, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMNM's market cap?
Immunome, Inc. has a market capitalization of $1.97 billion, making it a small-cap company.
Does IMNM pay dividends?
No, Immunome, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
Explore stocks similar to IMNM for comparison